Abbisko Cayman (HKG:2256) recorded a profit of 28.3 million yuan for the year 2024, compared with a loss of 431.6 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse stated.
Earnings per share were 0.04 yuan in the year, while the company had incurred a loss per share of 0.67 yuan in the corresponding period last year.
The drugmaker's revenue rose by 2,544% year over year to 504 million yuan from 19.1 million yuan a year prior.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。